AMGN Stock Summary and Trading Ideas (Amgen | NASDAQ:AMGN)

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen trades on the NASDAQ stock market under the symbol AMGN.

As of April 2, 2026, AMGN stock price declined to $346.20 with 583,166 million shares trading.

AMGN has a beta of 0.40, meaning it tends to be less sensitive to market movements. AMGN has a correlation of 0.06 to the broad based SPY ETF.

AMGN has a market cap of $186.63 billion. This is considered a Large Cap stock.

Last quarter Amgen reported $10 billion in Revenue and $5.29 earnings per share. This beat revenue expectation by $402 million and exceeded earnings estimates by $.54.

In the last 3 years, AMGN traded as high as $391.29 and as low as $211.71.

The top ETF exchange traded funds that AMGN belongs to (by Net Assets): VTI, VOO, QQQ, SCHD, IVV.

AMGN has underperformed the market in the last year with a price return of +15.9% while the SPY ETF gained +17.9%. However, in the short term, AMGN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.5% vs -3.8% return in SPY. But in the last 2 weeks, AMGN shares have been beat by the market, returning -1.5% compared to an SPY return of -0.9%.

AMGN support price is $347.97 and resistance is $358.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMGN shares will trade within this expected range on the day.